Abstract
Why diabetes is associated with abnormally high susceptibility to infection remains unknown, although two major antibacterial proteins, lysozyme and lactoferrin, have now been shown to specifically bind glucose–modified proteins bearing advanced glycation end products (AGEs). Exposure to AGE–modified proteins inhibits the enzymatic and bactericidal activity of lysozyme, and blocks the bacterial agglutination and bacterial killing activities of lactoferrin. Peptide mapping revealed a single AGE binding domain in lysozyme and two AGE binding domains in lactoferrin; each domain contains a 17– to 18– amino acid cysteine–bounded loop motif (CX15–16C) that is markedly hydrophilic. Synthetic peptides corresponding to these motifs in lysozyme and lactoferrin exhibited AGE binding activity, and similar domains are also present in other antimicrobial proteins. These results suggest that elevated levels of AGEs in tissues and serum of diabetic patients may inhibit endogenous antibacterial proteins by binding to this conserved AGE–binding cysteine–bounded domain ‘ABCD’ motif, thereby increasing susceptibility to bacterial infections in the diabetic population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
206,07 € per year
only 17,17 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Monnier, V.M. & Cerami, A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Science 211, 491–454 (1981).
Bucala, R., Vlassara, H. & Cerami, A. in Post-Translational Modifications of Proteins (eds Harding, J.J. Crabbe & M.J.C.) Ch 2, 53–79 (CRC Press, Boca Raton, Florida, 1992).
Vlassara, H., Bucala, R. & Striker, L. Pathogenic effects of advanced glycosylation: Biochemical, biological, and clinical implications for diabetes and aging. J. lab. Invest. 70, 138–151 (1994).
Moutshen, M.P., Scheen, A.J. & Lefebvre, P.J. Impaired immune responses in diabetes mellitus: Analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabetes Metab. (Paris) 18, 187–207 (1992).
Philips, D. The three-dimensional structure of an enzyme molecule. Sci. Am. 215, 78–90 (1966).
Anderson, B., Baker, H.M., Norris, G.E., Rumball, S.V. & Baker, E.N. Apo-lactoferrin structure demonstrates ligand-induced conformational change in transferrins. Nature 344, 784–787 (1992).
Reiter, B. & Oram, J.D. Bacterial inhibitors in milk and other biological fluids. Nature 216, 643–658 (1969).
Tenovuo, J., Lumikari, M. & Soukka, T. Salivary lysozyme, lactoferrin and peroxidases: Antibacterial effects on cariogenic bacteria and clinical applications in preventive dentistry. Proc. Finn. Dent. Soc. 87, 197–208 (1991).
Velikov, V.K. et al. Humoral factors of general and local immunity in diabetes mellitus. Ter. Arkh. 57, 20–22 (1985).
Muratsu, K. & Morioka, T. Levels of salivary lysosyme, lactoperoxidase and lactoferrin in diabetic hamsters. Infect. Immun. 48, 389–394 (1985).
Tenovuo, J. et al. Immunoglobulins and innate antimicrobial factors in whole saliva of patients with insulin-dependent diabetes mellitus. J. dent. Res. 65, 62–66 (1986).
Oberg, G. et al. Bactericidal proteins and neutral proteases in diabetes neutrophils. Diabetologia 29, 426–429 (1986).
Lechowski, R. et al. Serum lysosyme activity and nitroblue tetrazolium reduction test in dogs with diabetes mellitus. Zentralbl. Veterinaermed. 38, 530–503 (1991).
Ben-Aryeh, H. et al. Oral health and salivary composition in diabetic patients. J. diabetes Complications 7, 57–62 (1993).
Makita, Z., Vlassara, H., Cerami, A. & Bucala, R. Immunochemical detection of advanced glycosylation end products. J. biol. Chem. 267, 5133–5138 (1992).
Soukka, T., Tenovuo, J. & Rundegren, J. Agglutination of Streptococcus mutans serotype C cells but inhibition of Porphyromonas gingivalis autoaggregation by human lactoferrin. Arch. Oral Biol. 38, 227–232 (1993).
Perillie, P.E. & Finch, S.C. in Lysosyme (eds Osserman, E.F., Canfield, R.E. & Beychok, S.) Ch. 31, 359–372 (Academic, New York and London, 1974).
Schmidt, A.M. et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. biol. Chem. 267, 14987–14997 (1992).
Vlassara, H., Brownlee, M. & Cerami, A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J. exp. Med. 164, 1301–1309 (1986).
Casey, J.I. in Diabetes Mellitus Theory and Practice (eds Rifkin, H. & Porte D. Jr) Ch. 37, 617–625 (Elsevier, New York, Amsterdam, London, 1991).
Takada, K., Ohno, N. & Yadomae, T. Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo. Infect. Immun. 62, 1171–1175 (1994).
Bellamy, W. et al. Identification of the bactericidal domain of LF. Biochim. biophys. Acta 1121, 130–136 (1992).
Gabay, J.E. & Almeida, R.P. Antibiotic peptides and serine protease homologs in human polymorphonuclear leukocytes: Defensins and azurocidin. Curr. Opin. Immun. 5, 97–102 (1993).
Lehrer, R.I. Defensins: Antimicrobial and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol. 11, 105–128 (1993).
Johnstone, A.P., Thunberg, A.L. & Kindt, T.J. Homogeneous rabbit immunoglobulin lacking group a allotypes: Amino acid sequence analysis of the heavy chain. Biochemistry 17, 1337–1343 (1978).
Mahoney, W.C. & Hermodson, M.A. High-yield cleavage of tryptophophnyl peptide bonds by o-iodosobenzoic acid. Biochemistry 18, 3810–4814 (1979).
Hopp-Woods method. Analyzed with MacVector 4.0 software, New Haven, Connecticut, and Lasergene, DNASTAR, Madison, Wisconsin.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, Y., Tan, A. & Vlassara, H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif. Nat Med 1, 1057–1061 (1995). https://doi.org/10.1038/nm1095-1057
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1095-1057
This article is cited by
-
Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies
Nutrition & Metabolism (2018)
-
Nε-(Carboxymethyl)lysine Modification of Elastin Alters Its Biological Properties: Implications for the Accumulation of Abnormal Elastic Fibers in Actinic Elastosis
Journal of Investigative Dermatology (2012)
-
AGE restriction in diabetes mellitus: a paradigm shift
Nature Reviews Endocrinology (2011)
-
Effect of Chemical Chaperones on Glucose-Induced Lysozyme Modifications
The Protein Journal (2011)
-
Advanced glycation end products strongly activate platelets
European Journal of Nutrition (2009)